TORONTO, Ontario — November 13, 2025: Telo Genomics announced it will present its groundbreaking individual-cell MRD risk-assessment technology at the Myeloma Canada MRD Implementation Summit 2025. The presentation, led by Dr. Yulia Shifrin, will showcase early clinical results demonstrating how the company’s blood-based MRD workflow, powered by its TeloView® multi-factor telomere analytics platform, identifies high-risk cancer cell populations at single-cell resolution. This advancement moves MRD assessment beyond simple detection to predictive risk profiling, marking a major evolution in clinical decision-support for multiple myeloma.
Science Significance
Telo Genomics’ MRD platform introduces a new scientific dimension to cancer monitoring by integrating 3D telomere architecture, genomic instability analysis, and single-cell profiling into a unified risk-assessment system. Early findings reveal that myeloma patients exhibit distinct structural and genomic signatures in residual cancer cells that correlate strongly with relapse probability. Unlike conventional MRD methods—which rely solely on quantitative disease thresholds—Telo’s approach provides a quantifiable relapse-risk score based on the biological aggressiveness of individual cells. This represents a shift toward precision oncology, where MRD becomes not only a detection metric but a predictive biomarker powered by advanced imaging, molecular analytics, and AI-driven interpretation.
Regulatory Significance
The technology emerges at a pivotal time, as the FDA’s Oncologic Drugs Advisory Committee unanimously accepted MRD as a clinical endpoint for accelerated approval in multiple myeloma. This regulatory milestone elevates MRD from an investigational tool to a validated surrogate endpoint, making its accuracy and depth more critical than ever. Telo’s single-cell risk-assessment capability aligns with evolving regulatory expectations emphasizing clinical relevance, analytical precision, and risk-based outcome prediction. As regulators increasingly integrate MRD into therapeutic evaluation, Telo’s platform positions itself as a high-value diagnostic asset within compliant laboratory frameworks and emerging MRD-driven trial designs.
Business Significance
Advertisement
The global MRD testing market is projected to exceed USD 4.1 billion by 2032, fueled by adoption in oncology and personalized medicine. Telo Genomics enters this expanding sector with a differentiated MRD technology that offers clinical insights beyond existing sequencing and flow-cytometry-based platforms. By presenting at a national summit attended by clinicians, researchers, and decision-makers, Telo strengthens its position as an innovation leader in diagnostic intelligence. The company’s telomere-based assays, backed by over 160 peer-reviewed publications and 30+ clinical studies, provide a strong scientific and commercial foundation for partnerships across hospitals, diagnostic labs, and drug-development programs. The growing need for early relapse prediction, stratification of precursors such as MGUS and SMM, and integration with oncology workflows further enhances the company’s commercial trajectory.
Patients’ Significance
Multiple myeloma remains an incurable blood cancer, with 35,000 new U.S. cases each year and most patients eventually relapsing due to undetected residual cells. Telo’s technology offers patients a new layer of predictive clarity, enabling clinicians to identify relapse-driving cells before clinical symptoms appear. This could lead to earlier intervention, optimized treatment selection, and more personalized monitoring strategies. For individuals with MGUS and smoldering myeloma, whose progression risk varies widely, single-cell profiling offers the potential to distinguish which patients will progress rapidly and which can be safely monitored. By enhancing the precision of patient stratification and therapeutic planning, Telo’s MRD platform stands to significantly improve outcomes and reduce the physical and economic burden of repeated relapses.
Policy Significance
As healthcare systems prioritize value-based care and precision diagnostics, Telo’s approach supports policymaking focused on early detection, proactive intervention, and improved long-term outcomes. The integration of MRD as a regulatory endpoint positions advanced diagnostics as essential contributors to drug-approval frameworks, reimbursement models, and guideline development. This technology aligns with national efforts to reduce cancer-related healthcare costs by preventing late-stage relapse events and minimizing unnecessary treatments. By enabling evidence-based MRD adoption across academic and community settings, Telo’s platform supports broader policies aimed at equitable access to next-generation diagnostics.
Telo Genomics’ presentation at the Myeloma Canada MRD Implementation Summit marks a transformative moment for MRD testing and precision oncology. By extending MRD beyond simple enumeration to individual-cell risk analysis, the company is redefining how relapse risk is understood, monitored, and clinically acted upon. With strong scientific validation, growing regulatory relevance, and a rapidly expanding commercial opportunity, Telo’s breakthrough technology is poised to reshape the future of multiple myeloma diagnostics and elevate the standard of care for thousands of patients worldwide.
Source: Telo Genomics press release
